BDSI BioDelivery Sciences International Inc.

4.65
-0.03  -1%
Previous Close 4.68
Open 4.66
Price To Book 11.07
Market Cap 329931190
Shares 70,952,944
Volume 1,177,495
Short Ratio
Av. Daily Volume 1,048,097

NewsSee all news

  1. What Makes BioDelivery (BDSI) a New Buy Stock
  2. BioDelivery (BDSI) Up 7.8% Since Last Earnings Report: Can It Continue?
  3. BDSI expects $50 million in latest public offering
  4. BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
  5. BioDelivery Sciences International, Inc. Announces Pricing of Public Offering of Common Stock

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine
Pain

Latest News

  1. What Makes BioDelivery (BDSI) a New Buy Stock
  2. BioDelivery (BDSI) Up 7.8% Since Last Earnings Report: Can It Continue?
  3. BDSI expects $50 million in latest public offering
  4. BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
  5. BioDelivery Sciences International, Inc. Announces Pricing of Public Offering of Common Stock
  6. The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug
  7. BDSI announces public offering after paying $30M for drug rights
  8. BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock
  9. BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
  10. BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know
  11. Lifshitz & Miller LLP Announces Investigation of Alta Mesa Resources, Inc., American Renal Associates LLC, Belden, Inc., BioDelivery Sciences, Inc., Blue Valley Bank Corp., Bridgepoint Education, Inc., and Care.com, Inc.
  12. Edited Transcript of BDSI earnings conference call or presentation 14-Mar-19 8:30pm GMT
  13. Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
  14. Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
  15. BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up
  16. Biodelivery Sciences International Inc (BDSI) Q4 2018 Earnings Conference Call Transcript
  17. BioDelivery: 4Q Earnings Snapshot
  18. BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations
  19. BioDelivery Sciences International, Inc. to Host Earnings Call
  20. Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma